Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.

Marcon, Ilaria Gioia; Valsecchi, Diletta; Durso, Lorenza; Premoli, Eleonora; Sangiorgi, Diego; Perrone, Valentina; Catena, Laura; Degli Esposti, Luca

Marcon, Ilaria Gioia; Valsecchi, Diletta; Durso, Lorenza; Premoli, Eleonora; Sangiorgi, Diego; Perrone, Valentina; Catena, Laura; Degli Esposti, Luca.

Affiliation

Marcon IG; Novartis Farma S.p.A., 20154, Milan, Italy.
Valsecchi D; Novartis Farma S.p.A., 20154, Milan, Italy.
Durso L; Novartis Farma S.p.A., 20154, Milan, Italy.
Premoli E; Novartis Farma S.p.A., 20154, Milan, Italy.
Sangiorgi D; CliCon S.r.l. Società Benefit, Health, Economics and Outcomes Research, Via Murri, 9, 40137, Bologna, Italy.
Perrone V; CliCon S.r.l. Società Benefit, Health, Economics and Outcomes Research, Via Murri, 9, 40137, Bologna, Italy.
Catena L; Novartis Farma S.p.A., 20154, Milan, Italy.
Degli Esposti L; CliCon S.r.l. Società Benefit, Health, Economics and Outcomes Research, Via Murri, 9, 40137, Bologna, Italy. luca.degliesposti@clicon.it.

Adv Ther ; 40(9): 3875-3895, 2023 09.

Article in En | MEDLINE | ID: mdl-37368101

Subject(s)
Key words

BRAF inhibitors; BRAF mutations; Chemotherapy; Immunotherapy; MEK inhibitors; Metastatic melanoma; Skin cancer; Target therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Brain Neoplasms / Melanoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2023 Document type: Article Affiliation country: Italia Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google